InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,751.07
(
0.90%
)
US TECH 100
19,476.00
(
1.10%
)
Dow Jones
42,352.75
(
0.81%
)
Brent Oil
77.97
(
0.00%
)
Bitcoin
61,920.25
(
-0.25%
)
Post# of 30387
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

HALF FULL GLASS

Send PM Follow Ignore
Followers 3
Posts 3535
Boards Moderated 0
Alias Born 06/15/2005

HALF FULL GLASS

Re: None

Wednesday, 03/07/2012 11:34:59 PM

Wednesday, March 07, 2012 11:34:59 PM

Post# of 30387
Brian Druker, the doctor and cancer researcher who helped develop Gleevec, an early gene-based leukemia medicine made by Novartis AG (NOVN) of Switzerland, said the analysis shows the need for “better tools to identify cancer at earlier stages, when it is far less complex.” Druker directs the Knight Cancer Institute at the Oregon Health & Science University in Portland.

Entire story is included in the link below

http://www.bloomberg.com/news/2012-03-07/cancer-scans-may-give-false-picture-of-genes-driving-disease-study-finds.html
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up